Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a leading medical device company dedicated to providing non-invasive and cost-effective treatments for non-melanoma skin cancer and keloids. Utilizing a proprietary low-energy x-ray radiation technology known as Superficial Radiation Therapy (SRT), Sensus Healthcare has made significant advancements in the field over more than a decade of dedicated research and development. The company’s flagship products, the SRT-100™ and SRT-100 Vision™, effectively and safely treat a variety of oncological and non-oncological skin conditions, including basal cell and squamous cell skin cancers, as well as keloids.
Based in Boca Raton, Florida, Sensus Healthcare focuses on creating innovative, minimally-invasive solutions that address critical medical needs. The company has recently announced a multi-faceted collaboration with CureRays, a radiation oncology specialist organization headquartered in Atlanta and Grass Valley, California. This partnership aims to enhance the reach and efficacy of Sensus's SRT technology, further solidifying its position as a leader in the non-invasive treatment market.
Sensus Healthcare generates the majority of its revenue from customers within the United States, offering products and services that meet the highest standards of safety and effectiveness. The company’s proprietary technology has been incorporated into its diverse portfolio, which includes the SRT-100™, SRT-100 Vision™, and a comprehensive Sentinel service program that ensures optimal device performance and customer satisfaction.
Investors and stakeholders are encouraged to stay informed about Sensus Healthcare’s latest developments. Recently, the company announced it would hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones. This call will offer an in-depth overview of the company’s financial health and strategic initiatives.
For more detailed information about Sensus Healthcare, its innovative technology, products, and recent news, please visit Sensus Healthcare’s official website.
Sensus Healthcare (NASDAQ: SRTS) has announced the resumption of its share repurchase program, allowing for the purchase of up to $3.0 million of common stock in open-market transactions. The program, initially approved by the Board of Directors in August 2023, has already seen the repurchase of 9,427 shares.
CEO Joe Sardano stated that the company views the current stock price as a compelling opportunity for repurchases, expressing confidence in growth prospects. The company successfully completed a similar $3 million repurchase program in 2022.
The timing and volume of share repurchases will be determined by management based on capital needs, stock price, and market conditions. The program may include open-market purchases, block trades, and exchange transactions, with the flexibility to suspend or discontinue at any time.
Sensus Healthcare (NASDAQ: SRTS) reported strong Q4 and full-year 2024 results, marking its fifth consecutive quarter of profitability. Q4 revenues reached $13.1 million with net income of $1.5 million ($0.09 per diluted share). The company achieved record shipments of 39 SRT systems in Q4 and 115 systems for the full year, representing increases of 18% and 74% respectively.
Full-year 2024 revenues grew 71% to $41.8 million, with net income of $6.6 million ($0.41 per diluted share). The company maintains a strong financial position with $22.1 million in cash and no debt. Management expects Q1 2025 sales to be lower than Q1 2024, though anticipating full-year growth. The company continues to expand its Fair Deal Agreement program and plans to re-submit its TDI 510(k) application in H1 2025.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has announced its upcoming participation in The Microcap Conference 2025. The event will take place from January 28-30, 2025, in Atlantic City, N.J.
The company's management team will deliver a corporate presentation on Thursday, January 30, 2025, at 2:00 PM Eastern Time in Studio 2 of the Borgata Hotel Casino & Spa. During the conference, management will engage in one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally-invasive treatments for skin conditions, has scheduled its 2024 fourth quarter and full year financial results announcement for Wednesday, February 5, 2025. The company will host a conference call at 4:30 p.m. Eastern time to discuss results and provide a business update.
Participants can pre-register for the call through a provided link for a unique dial-in number, or join by dialing 844-481-2811 (U.S./Canada) or 412-317-0676 (International). The call will be webcast live and available for replay until March 5th, with replay numbers provided for U.S., Canada, and International callers.
Sensus Healthcare (NASDAQ: SRTS) has partnered with Pompano Veterinary Oncology to pioneer mobile superficial radiotherapy (SRT) treatment for companion animals in South Florida. The veterinary practice has purchased an SRT-100™ system to provide treatments via a mobile van, both for home visits and veterinary clinics.
This marks the fourth SRT system being used for animal treatment, with two systems at Colorado State University School of Veterinary Medicine and one at Beit Veri College in Tel Aviv. The mobile service will complement Pompano Veterinary Oncology's existing treatments, including chemotherapy, immunotherapy, surgery, and tumor-specific electroporation therapy.
Sensus Healthcare (NASDAQ: SRTS) reported strong Q3 2024 financial results with revenues reaching $8.8 million, a 127% increase from $3.9 million in Q3 2023. The company achieved net income of $1.2 million ($0.07 per diluted share) compared to a net loss of $1.5 million in the prior year. Key highlights include shipping 27 systems, entering seven new Fair Deal Agreements for SRT-100 Vision units, and maintaining a strong balance sheet with $22.6 million in cash and no debt. The company expects to have over 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by year-end.
Sensus Healthcare (SRTS) reported strong Q3 2024 financial results with revenues more than doubling to $8.8 million compared to $3.9 million in Q3 2023. The company achieved net income of $1.2 million ($0.07 per diluted share) versus a net loss of $1.5 million in the prior year. They shipped 27 systems during the quarter and signed a significant Fair Deal Agreement with Platinum Dermatology, a network of 130 dermatology clinics. The company maintained a strong financial position with $22.6 million in cash and no debt. Gross profit margin improved to 59.3% from 51.0% year-over-year.
Sensus Healthcare (Nasdaq: SRTS), a medical device company focused on non-invasive treatments, announces its upcoming Third Quarter 2024 financial results conference call scheduled for November 14, 2024, at 4:30 p.m. Eastern time. Management will discuss Q3 2024 financial results, provide business updates, and review recent and upcoming milestones. The call will be accessible via pre-registration or direct dial-in, with a replay available until December 14, 2024. A webcast will also be available through the company's website.
Sensus Healthcare (Nasdaq: SRTS) has shipped an SRT system to Providence Swedish Hospital in Seattle, marking its latest success in expanding to community hospital oncology departments. The sale highlights growing interest in superficial radiotherapy (SRT) for treating non-melanoma skin cancer and keloids on an outpatient basis.
Dr. Christopher Loiselle, Medical Director of Radiation Oncology at Swedish Cancer Institute, praised the SRT system as state-of-the-art for treating skin cancers and other superficial conditions. Joe Sardano, CEO of Sensus Healthcare, expressed delight in Providence Swedish Hospital's recognition of SRT benefits and noted increasing inquiries from hospitals nationwide about offering non-invasive skin cancer treatments.
Sensus Healthcare (SRTS) reported strong Q2 2024 financial results, with revenues doubling to $9.2 million compared to Q4 2023. The company achieved net income of $1.6 million ($0.10 per diluted share) and positive Adjusted EBITDA of $2.1 million. Key highlights include:
- Shipped 23 systems, including 3 SRT-100 units to Asia
- Signed 15 'Fair Deal Agreements' for SRT-100 Vision units
- Ended Q2 with $19 million in cash and no debt
- Accounts receivable increased to $18.3 million
The company's growth was driven by higher superficial radiotherapy unit sales and international expansion efforts, particularly in Asia. Management expects the Fair Deal Agreement program to generate recurring revenue starting in 2025.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What is Sensus Healthcare, Inc.?
What products does Sensus Healthcare offer?
What is Superficial Radiation Therapy (SRT)?
Where is Sensus Healthcare based?
What recent collaborations has Sensus Healthcare announced?
How does Sensus Healthcare generate its revenue?
What is the Sentinel service program?
When is the next conference call for Sensus Healthcare?
Where can I find more information about Sensus Healthcare?
What conditions can Sensus Healthcare’s devices treat?
